Sep. 3 at 12:34 PM
$CELU update from management:
✅ Regained Nasdaq compliance – This removes the risk of delisting, which is often a major overhang on investor confidence.
✅ Debt fully retired – Paying off
$32M in secured debt plus
$9.6M interest significantly strengthens the balance sheet and removes a security interest on assets.
✅ Restructuring completed – Establishing subsidiaries signals clearer organization and operational focus.
✅ Growth outlook – CEO highlighted renewed wound care sales growth, advancing late-stage 510(k) products, and expansion into stem cell products in Florida and beyond.
✅ Access to working capital – Signals improved liquidity and ability to fund operations without distressed financing.
